Production of recombinant immunotherapeutics for anticancer treatment the role of bioengineering

Bioengineered

Volumn 4, Issue 5, 2013, Pages

  Pranchevicius, Maria Cristina S ^a   Vieira, Thiessa R ^a  

^a UNIVERSIDADE FEDERAL DO TOCANTINS   (Brazil)

Author keywords

Antibodies; Cancer vaccines; Fusion proteins; Immunostimulants; Immunotherapy; Immunotoxins; Recombinant drugs

Indexed keywords

AFLIBERCEPT; ALEMTUZUMAB; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CETUXIMAB; DENILEUKIN DIFTITOX; DNA VACCINE; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; IODINE 131; IPILIMUMAB; IRINOTECAN; OFATUMUMAB; PANITUMUMAB; PERTUZUMAB; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SIPULEUCEL T; TOSITUMOMAB; TRASTUZUMAB; WART VIRUS VACCINE; YTTRIUM 90; ANTIBODY; ANTIBODY CONJUGATE; BACTERIAL TOXIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; IMMUNOTOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST METASTASIS; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; CUTANEOUS T CELL LYMPHOMA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL DISEASE; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; IMMUNOSTIMULATION; KAPOSI SARCOMA; KIDNEY METASTASIS; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMABLASTIC LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; STOMACH CANCER; BIOENGINEERING; BIOSYNTHESIS; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; BACTERIAL TOXINS; BIOENGINEERING; CANCER VACCINES; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 84883384716     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010; 17:21. PMID:20331869. http://dx.doi.org/10.1186/1423-0127-17-21.
2. Lechner MG, Russell SM, Bass RS, Epstein AL. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy 2011; 3:1317-40. PMID:22053884. http://dx.doi.org/10.2217/imt.11.115.
3. Liu MA. Cancer vaccines. Philos Trans R Soc Lond B Biol Sci 2011; 366:2823-6. PMID:21893546. http://dx.doi.org/10.1098/rstb.2011.0101.
4. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther 2012; 135:44-53. PMID:22484806. http://dx.doi.org/10.1016/j.pharmthera.2012.03.006.
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9. PMID:22193102. http://dx.doi.org/10.1038/nature10673.
6. Moschella F, Proietti E, Capone I, Belardelli F. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci 2010; 1194:169-78. PMID:20536466. http://dx.doi.org/10.1111/j.1749-6632.2010.05464.x.
7. Immunotherapy [Internet]. [place unknown]: American Cancer Society; 2012 May 5 [cited 2012 December 20]. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003013-pdf.pdf
8. Coventry BJ, Ashdown ML. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 2012; 4:215-21. PMID:22904643. http://dx.doi.org/10.2147/CMAR.S33979.
9. Eriksson F. Tumor immunology. In: Eriksson F, ed. Novel approaches for cancer immunotherapy. Stockholm: Karolinska Instituet, 2008: 12.
10. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011; 26:1-64. PMID:21355777. http://dx.doi.org/10.1089/cbr.2010.0902.
11. Bele T. Treating cancer with vaccine. Webmed Central Immunotherapy 2012; 3:1-7.
12. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010:1-14. PMID:20706612. http://dx.doi.org/10.1155/2010/596432.
13. Mäkelä PH. Vaccines, coming of age after 200 years. FEMS Microbiol Rev 2000; 24:9-20. PMID:10640596.
14. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin 2009; 5:671-89. PMID:19684468. http://dx.doi.org/10.4161/hv.5.10.9370.
15. Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006; 95:115-45. PMID:16860657. http://dx.doi.org/10.1016/S0065-230X(06)95004-0.
16. Kumar VP, Prasanthi S, Lakshmi VRS, Santosh MVS. Cancer vaccines: a promising role in cancer therapy. Acad J Cancer Res 2010; 3:16-21.
17. Gulley JL, Arlen PM, Hodge JW, Schlom J. Vaccines and Immunostimulants. In: Hong WK, et al, eds. Holland Frei Cancer Medicine. 8th ed. Shelton, Connecticut: People's Medical Publishing House, 2010: 725-36.
18. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol 2010; 2010:697158. PMID:20936120. http://dx.doi.org/10.1155/2010/697158.
19. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613. PMID:22395641. http://dx.doi.org/10.1093/jnci/djs033.
20. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 2011; 10:3. PMID:21211062. http://dx.doi.org/10.1186/1476-4598-10-3.
21. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010; 16:217-30. PMID:20331326.
22. Bharadwaj M, Hussain S, Nasare V, Das BC. HPV & HPV vaccination: issues in developing countries. Indian J Med Res 2009; 130:327-33. PMID:19901442.
23. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186:1325-31. PMID:21248270. http://dx.doi.org/10.4049/jimmunol.0902539.
24. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9. PMID:19536890. http://dx.doi.org/10.1002/cncr.24429.
25. Nemunaitis J. Multifunctional vaccines in cancer: the 'triad' approach. Expert Rev Vaccines 2011; 10:713-5. PMID:21692693. http://dx.doi.org/10.1586/erv.11.78.
26. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38. PMID:20305665. http://dx.doi.org/10.1038/nrd3003.
27. Oldham RK, Dillman RO. Monoclonal antibodies i cancer therapy: 25 years of progress. J Clin Oncol 2008; 26:1774-7. PMID:18398141. http://dx.doi.org/10.1200/JCO.2007.15.7438.
28. Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol 2011; 28:518-29. PMID:21473941. http://dx.doi.org/10.1016/j.nbt.2011.03.021.
29. Dillman RO. Monoclonal antibody therapy. In: Oldham RK, Dillman RO, ed(s). Principles of Cancer Biotherapy. 4th ed. Dordrecht: Kluwer Academic Publishers, 2003: 329-90.
30. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8(Suppl):S19-26. PMID:11927283. http://dx.doi.org/10.1016/S1471-4914(02)02306-7.
31. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003; 30(Suppl 17):1-5. PMID:14710396. http://dx.doi.org/10.1053/j.seminoncol.2003.10.002.
32. Grillo-López AJ. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 2003; 3:767-79. PMID:14686699. http://dx.doi.org/10.1586/14737140.3.6.767.
33. Vogel CL, Franco SX. Clinical experience with trastuzumab (herceptin). Breast J 2003; 9:452-62. PMID:14616939. http://dx.doi.org/10.1046/j.1524-4741.2003.09602.x.
34. Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J 2011; 6:16-27. PMID:21170983. http://dx.doi.org/10.1002/biot.201000381.
35. Kamionka M. Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol 2011; 12:268-74. PMID:21050165. http://dx.doi.org/10.2174/138920111794295693.
36. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011; 7:313-21. PMID:21346417. http://dx.doi.org/10.4161/hv.7.3.14207.
37. De Muynck B, Navarre C, Boutry M. Production of antibodies in plants: status after twenty years. Plant Biotechnol J 2010; 8:529-63. PMID:20132515. http://dx.doi.org/10.1111/j.1467-7652.2009.00494.x.
38. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33. PMID:9704735.
39. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al.; German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326-31. PMID:11520778. http://dx.doi.org/10.1182/blood.V98.5.1326.
40. Utku N. New approaches to treat cancer -what they can and cannot do. Biotechnol Healthc 2011; 8:25-7. PMID:22479231.
41. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncol 2012; 13:25-32. PMID:22153890. http://dx.doi.org/10.1016/S1470-2045(11)70336-9.
42. Bast RC Jr., Zalutsky MR, Kreitman RJ, Frankel AE. Monoclonal Serotherapy. In: Hong WK, et al, eds. Holland Frei Cancer Medicine. 8th ed. Shelton, Connecticut: People's Medical Publishing House, 2010: 710-24.
43. Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull 2012; 104:41-59. PMID:23118261. http://dx.doi.org/10.1093/bmb/lds032.
44. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008; 222:9-27. PMID:18363992. http://dx.doi.org/10.1111/j.1600-065X.2008.00601.x.
45. Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J 2012; 18:450-6. PMID:23006951. http://dx.doi.org/10.1097/PPO.0b013e31826aef4a.
46. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12:14. PMID:22896759.
47. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706-12. PMID:15867200. http://dx.doi.org/10.1200/JCO.2005.00.232.
48. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44. PMID:17442997. http://dx.doi.org/10.1200/JCO.2006.09.6305.
49. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. PMID:17167137. http://dx.doi.org/10.1056/NEJMoa061884.
50. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76. PMID:18160686. http://dx.doi.org/10.1056/NEJMoa072113.
51. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45. PMID:15269313. http://dx.doi.org/10.1056/NEJMoa033025.
52. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007; 12:577-83. PMID:17522246. http://dx.doi.org/10.1634/theoncologist.12-5-577.
53. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27. PMID:20414205. http://dx.doi.org/10.1038/nri2744.
54. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16. PMID:20414204. http://dx.doi.org/10.1038/nri2761.
55. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74. PMID:20811384. http://dx.doi.org/10.1038/nrd3229.
56. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-90. PMID:14573361. http://dx.doi.org/10.1016/j.tibtech.2003.08.007.
57. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol 2009; 525:1-27, xiii. PMID:19252861. http://dx.doi.org/10.1007/978-1-59745-554-1_1.
58. Madhumathi J, Verma RS. Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012; 15:300-9. PMID:22647353. http://dx.doi.org/10.1016/j.mib.2012.05.006.
59. Hornig N, Färber-Schwarz A. Production of bispecific antibodies: diabodies and tandem scFv. Methods Mol Biol 2012; 907:713-27. PMID:22907382.
60. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16:495-503. PMID:21511052. http://dx.doi.org/10.1016/j.drudis.2011.04.003.
61. Pennell CA, Erickson HA. Designing immunotoxins for cancer therapy. Immunol Res 2002; 25:177-91. PMID:11999171. http://dx.doi.org/10.1385/IR:25:2:177.
62. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8:E532-51. PMID:17025272. http://dx.doi.org/10.1208/aapsj080363.
63. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:1870-7. PMID:20212249. http://dx.doi.org/10.1200/JCO.2009.26.2386.
64. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-88. PMID:11208829.
65. Weidle UH, Schneider B, Georges G, Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 2012; 9:357-72. PMID:23162075.
66. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012; 38:484-93. PMID:22264850. http://dx.doi.org/10.1016/j.ctrv.2011.12.008.
67. Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer 2012; xx:1-13. PMID:23102896.